The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes

Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study

(2020) Michelle Rosenzwajg et al.   DIABETOLOGIA

An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice

(2020) Liliane Khoryati et al.   Science Immunology

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial

(2019) Jing He et al.   ANNALS OF THE RHEUMATIC DISEASES

Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients

(2019) Chunmiao Zhao et al.   BMC IMMUNOLOGY

Mucosal-Associated Invariant T Cell Features and TCR Repertoire Characteristics During the Course of Multiple Sclerosis

(2019) Edgar Carnero Contentti et al.   Frontiers in Immunology

A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism

(2018) Eleonora Trotta et al.   NATURE MEDICINE

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes

(2018) Jonathan T. Sockolosky et al.   SCIENCE

Reprogramming human T cell function and specificity with non-viral genome targeting

(2018) Theodore L. Roth et al.   NATURE

Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives

(2017) Ken-ichi Matsuoka   INTERNATIONAL JOURNAL OF HEMATOLOGY

Discovery of stimulation-responsive immune enhancers with CRISPR activation

(2017) Dimitre R. Simeonov et al.   NATURE

Multiplexed droplet single-cell RNA-sequencing using natural genetic variation

(2017) Hyun Min Kang et al.   NATURE BIOTECHNOLOGY

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease

(2016) John Koreth et al.   BLOOD

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

(2016) D. H. Charych et al.   CLINICAL CANCER RESEARCH

Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset

(2016) Susanne M. Cabrera et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Using GWAS to identify genetic predisposition in hepatic autoimmunity

(2016) G.J. Webb et al.   JOURNAL OF AUTOIMMUNITY

Human MAIT-cell responses to Escherichia coli : activation, cytokine production, proliferation, and cytotoxicity

(2016) Joana Dias et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes

(2016) Natalia Marek-Trzonkowska et al.   Journal of Translational Medicine

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial

(2016) John A. Todd et al.   PLOS MEDICINE

Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

(2015) Aixin Yu et al.   DIABETES

Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry

(2015) Kellee M. Miller et al.   DIABETES CARE

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

(2015) Michelle Rosenzwajg et al.   JOURNAL OF AUTOIMMUNITY

Thymic regulatory T cell niche size is dictated by limiting IL-2 from antigen-bearing dendritic cells and feedback competition

(2015) Brian M Weist et al.   NATURE IMMUNOLOGY

Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm

(2015) Eli R Zunder et al.   Nature Protocols

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

(2015) Jeffrey A. Bluestone et al.   Science Translational Medicine

The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells

(2014) A. Schneider et al.   JOURNAL OF IMMUNOLOGY

Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata

(2014) Emeline Castela et al.   JAMA Dermatology

Normalization of mass cytometry data with bead standards

(2013) Rachel Finck et al.   CYTOMETRY PART A

The Prevalence of Type 1 Diabetes in the United States

(2013) Andy Menke et al.   EPIDEMIOLOGY

Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

(2013) Wei Liao et al.   IMMUNITY

Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells

(2013) Rangsima Reantragoon et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

(2013) Antoinette Moran et al.   LANCET

Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease

(2013) K.-i. Matsuoka et al.   Science Translational Medicine

Regulatory T-Cell Therapy in Transplantation: Moving to the Clinic

(2013) Q. Tang et al.   Cold Spring Harbor Perspectives in Medicine

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

(2013) Agnès Hartemann et al.   Lancet Diabetes & Endocrinology

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs  -Cell Function

(2012) S. A. Long et al.   DIABETES

Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes

(2011) Stephanie A. McClymont et al.   JOURNAL OF IMMUNOLOGY

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

(2010) Yenkel Grinberg-Bleyer et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: Increased IL-17-Secreting T Cells in Children with New-Onset Type 1 Diabetes

(2010) A. K. Marwaha et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: Mechanisms of IL-2-Dependent Maintenance of Functional Regulatory T Cells

(2010) L. Barron et al.   JOURNAL OF IMMUNOLOGY

Genetics, pathogenesis and clinical interventions in type 1 diabetes

(2010) Jeffrey A. Bluestone et al.   NATURE

Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects

(2009) S. A. Long et al.   DIABETES

A Low Interleukin-2 Receptor Signaling Threshold Supports the Development and Homeostasis of T Regulatory Cells

(2009) Aixin Yu et al.   IMMUNITY

Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction

(2008) Qizhi Tang et al.   IMMUNITY